High Intratumoral Accumulation of Stealth Liposomal Doxorubicin in Sarcomas: Rationale for Combination with Radiotherapy

REFERENCES

• Gustafson P, Dreinhöfer KE, Rydholm A. Soft tissue sar-coma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994; 65: 47–50.
   PubMed Web of Science ®Google Scholar
• Williard WC, Hajdu SI, Casper ES, Brennan MF. Compari-son of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215: 269–75.
   PubMed Web of Science ®Google Scholar
• (Anonymous). Adjuvant chemotherapy for localised re-sectable soft-tissue sarcoma of adults: meta-analysis of indi-vidual data. Sarcoma meta-analysis collaboration. Lancet 1997; 350: 1647–54.
   Google Scholar
• Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int .1- Radiat Oncol Biol Phys 1998; 42: 563–72.
   PubMed Web of Science ®Google Scholar
• Kinsella TJ, Glatstein E. Clinical experience with intravenous radiosensitizers in unresectable sarcomas. Cancer 1987; 59: 908–15.
   PubMed Web of Science ®Google Scholar
• Martinez A, Goffinet DR, Donaldson SS, et al. Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofrac-tionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma. Int .1- Radiat Oncol Biol Phys 1985; 11: 123–1288.
   PubMed Web of Science ®Google Scholar
• Zambatis C, Skarlatos J, Koukourakis M, et al. High dose hypofractionated radiotherapy with concommitant 5-fluorou-racil in the treatment of advanced sarcomas of the bone. A Pilot study. Sarcoma 1998; 2: 25–8.
   PubMedGoogle Scholar
• Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus dox-orubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269–75.
   PubMed Web of Science ®Google Scholar
• Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990; 66: 862–7.
   Google Scholar
• Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treat-ment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537–45.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int .1- Radiat Biol 1990; 57: 55–64.
   PubMed Web of Science ®Google Scholar
• Sherman DM, Carabell SC, Belli JA, Hellman S. The effect of dose rate and adriamycin on the tolerance of thoracic radia-tion in mice. Int .1- Radiat Oncol Biol Phys 1982; 8: 45–51.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated lipo-somes. Cancer Res 1994; 54: 987–92.
   PubMed Web of Science ®Google Scholar
• Working PK, Newsman MS, Huang SK, Mayhew E, Vaage J, Lasic DD. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth® liposomes (Doxil"). J Liposom Res 1994; 4: 667–87.
   Google Scholar
• Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Stealth liposomal doxorubicin (Caelyx) and conventionally fractionated radiotherapy in the treatment of locally advanced non-small cell lung and head and neck cancer. J Clin Oncol 1999, (in press)
   Google Scholar
• World Health Organization. Handbook for reporting results of cancer treatment. Geneva: WHO Offset Publ, 1979: 48.
   Google Scholar
• Lasic DD, Martin FJ, Gabizon A, et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the ex-tended circulation times. Biochim Biophys Acta 1991; 1070: 187–92.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identifica-tion and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95–109.
   PubMed Web of Science ®Google Scholar
• Stewart S, Harrington KJ. The biodistribution and pharma-cokinetics of stealth liposomes in patients with solid tumors. Oncology 1997; 10 (Suppl 11): 33–7.
   Google Scholar
• Sakayama K, Masuno H, Miyazaki T, et al. Existence of lipoprotein lipase in human sarcomas and carcinomas. Jpn J Cancer Res 1994; 85: 515–21.
   PubMedGoogle Scholar
• Cobbs CS, Brenman JE, Aldape KD, et al. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995; 15: 727–30.
   Google Scholar
• Koukourakis MI, Giatromanolaki A, Kakolyris S, et al. Dif-ferent patterns of stromal and cancer cell thymidine phospho-rylase reactivity in non small cell lung cancer. Impact on neo-angiogenesis and survival. Br J Cancer 1998; 77: 1696–703.
   Google Scholar
• Harrington KJ, Rowlinson-Busza G, Uster PS, et al. Stealth® liposome encapsulated doxorubicin (SLED) and iodo-deoxyuridine (SLIIUDR) as radiation sensitizers in head and neck squamous cell cancer xenograft tumors (HNSCCXT). Proc Am Soc din Oncol 1998 (abstr 881).
   Google Scholar
• Hug EB, Fitzek MM, Liebsch NJ, Munzenrider JE. Locally challenging osteo and chondrogenic tumors of the axial skele-ton: results of combined proton and photon radiation radia-tion therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 1995; 31: 467–76.
   PubMed Web of Science ®Google Scholar